Chart Events
Performance Outlook
| Previous Close | 35.49 |
| Open | 35.43 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1100 |
| Day's Range | 34.87 - 35.61 |
| 52 Week Range | 28.47 - 46.97 |
| Volume | |
| Avg. Volume | 5,210,877 |
| Market Cap | 71.997B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 13.07 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.90 (5.34%) |
| Ex-Dividend Date | Nov 17, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GSK
Related Research
- GSK plcAnalyst Report: GSK plcIn the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.RatingFair ValueEconomic MoatyesterdayMorningstar
- PR Newswire
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
- News Direct
The Year of the Tripledemic
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of whic...
- GlobeNewswire
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics GSK to advance up to eight preclinical programs Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency, a disease that impacts the lungs and liver
